Finasteride and dutasteride are prescription 5-alpha-reductase inhibitors used for benign prostatic hyperplasia (BPH) in men with an enlarged prostate. Both reduce the formation of dihydrotestosterone (DHT), which can gradually reduce prostate volume and lower the risk of BPH progression.
01. Finasteride vs Dutasteride for BPH: Key Clinical Differences
Finasteride and dutasteride belong to the same medication class: 5-alpha-reductase inhibitors (5-ARIs).
5-alpha-reductase converts testosterone into dihydrotestosterone. DHT is an important androgen within prostate tissue and contributes to prostate growth. Reducing DHT can gradually shrink androgen-sensitive prostate tissue.
For an overview of this medication class, see 5-Alpha-Reductase Inhibitors for BPH .
What is the primary difference between finasteride and dutasteride for BPH?
The primary pharmacological difference is which forms of 5-alpha-reductase each medication inhibits.
Finasteride predominantly inhibits type 2 5-alpha-reductase. Type 2 activity is particularly important within prostate tissue.
Dutasteride inhibits both type 1 and type 2 5-alpha-reductase. This is why dutasteride is sometimes described as a dual 5-alpha-reductase inhibitor.
This difference leads to stronger suppression of DHT measured in the blood. Current European Association of Urology guidance reports that continuous treatment reduces serum DHT by approximately 70% with finasteride and approximately 95% with dutasteride.
The difference inside the prostate is much smaller. The same guidance reports that both drugs reduce intraprostatic DHT by roughly 85% to 90%.
What do finasteride and dutasteride have in common?
Despite their pharmacological differences, the two medications overlap substantially in their BPH effects.
Both can:
- reduce DHT exposure within prostate tissue;
- gradually decrease prostate volume;
- improve urinary symptoms in men with prostate enlargement;
- produce modest improvement in maximum urinary flow;
- reduce the long-term risk of acute urinary retention;
- reduce the likelihood of needing BPH-related surgery;
- reduce serum PSA levels substantially;
- and cause sexual adverse effects in some men.
Neither drug works like an alpha blocker. Alpha blockers can relax smooth muscle and improve urinary flow relatively quickly. Finasteride and dutasteride change prostate biology gradually, so their full clinical benefit generally requires months.
For that class-level difference, see Alpha Blockers vs 5-Alpha-Reductase Inhibitors for BPH .
Finasteride for BPH
A selective type 2 5-alpha-reductase inhibitor. The usual BPH formulation is 5 mg once daily.
See the dedicated guide: Finasteride for BPH .
Dutasteride for BPH
A dual type 1 and type 2 5-alpha-reductase inhibitor. The usual BPH formulation is 0.5 mg once daily.
See the dedicated guide: Dutasteride for BPH .
02. How Do Finasteride and Dutasteride for BPH Differ?
The medications differ most clearly in enzyme selectivity, circulating DHT suppression and pharmacokinetics. Their differences in real-world BPH outcomes are less dramatic than their biochemical differences might suggest.
How do finasteride and dutasteride differ in mechanism and DHT suppression?
| Feature | Finasteride | Dutasteride |
|---|---|---|
| Drug class | 5-alpha-reductase inhibitor | 5-alpha-reductase inhibitor |
| 5-alpha-reductase inhibition | Primarily type 2 | Type 1 and type 2 |
| Approximate serum DHT reduction | About 70% | About 95% |
| Prostate-tissue DHT reduction | Approximately 85%–90% | Approximately 85%–90% |
| Typical BPH dose | 5 mg once daily | 0.5 mg once daily |
| Plasma elimination | Relatively short; measured in hours | Much longer; terminal half-life about 5 weeks at steady state |
| Onset of BPH benefit | Gradual | Gradual |
Dutasteride therefore produces more complete suppression of circulating DHT. That biochemical difference is real, but it should not be interpreted as proof that dutasteride will produce proportionally greater symptom improvement.
Which differences matter most in BPH treatment?
For most patients, the clinically important questions are not simply which drug suppresses the most serum DHT. More relevant considerations include prostate size, risk of progression, expected duration of therapy, PSA monitoring, adverse effects, other medicines and the individual treatment plan.
The European Association of Urology reports that 5-alpha-reductase inhibitors as a class can reduce prostate volume by approximately 18% to 28% and lower PSA by around 50% after six to twelve months.
After several years of therapy, 5-ARIs can also improve urinary symptom scores, modestly increase maximum urinary flow and reduce the risk of acute urinary retention and BPH-related surgery.
Direct comparative evidence cited by the EAU indicates that finasteride and dutasteride have broadly similar effectiveness for lower urinary tract symptoms.
The guideline does note a possible difference related to baseline gland size: finasteride has shown limited benefit in some studies involving prostates below about 40 mL, while dutasteride has evidence of benefit in men with prostate volumes between approximately 30 and 40 mL.
That observation does not establish dutasteride as the universally superior medication. Treatment still depends on the complete clinical picture.
03. Finasteride vs Dutasteride for BPH: Decision Factors, Limits and Overlap
What are the main limitations of comparing finasteride and dutasteride directly?
A simple “which drug is stronger?” comparison can be misleading.
Finasteride and dutasteride have been studied in different clinical trials, sometimes involving men with different prostate volumes, symptom severity and progression risk. Results from separate placebo-controlled studies cannot always be compared as though the populations were identical.
Dutasteride’s greater effect on circulating DHT also does not necessarily translate into a clinically meaningful advantage in every urinary outcome.
Both medications belong to a class designed primarily for long-term modification of BPH progression rather than immediate relief of urinary symptoms.
Which patient or disease factors can change the comparison?
5-alpha-reductase inhibitors tend to have their greatest clinical role when benign prostate enlargement is substantial enough that future progression is a concern.
Factors clinicians may consider include:
- measured or estimated prostate volume;
- severity and bother from lower urinary tract symptoms;
- PSA level interpreted in the appropriate clinical context;
- previous acute urinary retention;
- risk of future BPH progression;
- urinary flow and bladder emptying;
- whether faster symptom relief is also needed;
- other medicines and medical conditions;
- sexual-function priorities;
- and willingness to use long-term therapy.
Current EAU guidance recommends considering the 5-ARI class particularly in men with moderate-to-severe lower urinary tract symptoms who also have an increased risk of progression, such as substantial prostate enlargement.
04. When Does the Difference Between Finasteride and Dutasteride Matter Clinically?
How does this comparison affect the next BPH treatment decision?
The first decision is often whether a 5-alpha-reductase inhibitor is appropriate at all.
If rapid symptom relief is the main immediate goal, an alpha blocker may be considered because it acts much faster. In men with enlarged prostates and a meaningful risk of progression, a 5-ARI may be used alone or together with an alpha blocker depending on the clinical situation.
Once the 5-ARI class is considered appropriate, the choice between finasteride and dutasteride becomes a more specific treatment decision.
Dutasteride’s dual enzyme inhibition may be relevant in some situations, while finasteride has extensive long-term BPH outcome evidence and a substantially shorter elimination half-life.
Neither difference should be considered in isolation.
How do finasteride and dutasteride affect PSA monitoring?
Both medications lower serum prostate-specific antigen substantially. A reduction of approximately 50% is expected in many men after several months of treatment.
This matters because PSA continues to be used when assessing prostate cancer risk. Clinicians need to know that a patient is taking a 5-alpha-reductase inhibitor so that the PSA result can be interpreted correctly.
A new PSA baseline is generally established after treatment has had time to produce its expected effect. A confirmed PSA increase from the lowest value reached during treatment deserves clinical evaluation rather than being dismissed because the absolute PSA remains within a conventional reference range.
Do finasteride and dutasteride have different side effects?
Their adverse-effect profiles overlap because both alter androgen metabolism. The most clinically relevant effects discussed with men using 5-ARIs include:
- reduced libido;
- erectile dysfunction;
- reduced ejaculate volume or other ejaculatory changes;
- and breast tenderness or enlargement in a small proportion of patients.
Individual responses vary, and experiencing an adverse effect with one drug does not automatically predict the same experience with the other.
Dutasteride remains in the body much longer after treatment is stopped because of its long terminal half-life. Finasteride is eliminated from plasma much more quickly.
When should one option be evaluated separately from the other?
A clinician may reconsider the individual drug choice when treatment response, side effects, PSA behavior, medication interactions, prostate size or treatment goals change.
Lack of rapid improvement during the first few weeks does not necessarily mean either medication has failed, because 5-alpha-reductase inhibitors have a slow onset of clinical benefit.
Persistent or worsening symptoms despite adequate treatment can also indicate that the problem is not explained by prostate enlargement alone. Bladder dysfunction, urethral disease, substantial fixed obstruction or another urinary condition may require further evaluation.
Men with complications, persistent obstruction or inadequate response to medication may eventually need to discuss procedural treatment rather than simply switching between two medications in the same class.
Finasteride vs Dutasteride for BPH: Quick Comparison
| Clinical question | Finasteride | Dutasteride |
|---|---|---|
| Same medication class? | Yes — 5-alpha-reductase inhibitor | Yes — 5-alpha-reductase inhibitor |
| Main enzyme target | Type 2 | Type 1 and type 2 |
| Which suppresses serum DHT more? | Less complete suppression | More complete suppression |
| Do both shrink enlarged prostate tissue? | Yes | Yes |
| Do both reduce PSA? | Yes, typically substantially | Yes, typically substantially |
| Are they fast symptom-relief medications? | No | No |
| Can they reduce BPH progression risk? | Yes, in appropriately selected men | Yes, in appropriately selected men |
| Can sexual adverse effects occur? | Yes | Yes |
| Is one universally better? | No. Greater biochemical DHT suppression does not establish a universally superior clinical choice. | |
Summary
Finasteride and dutasteride are closely related 5-alpha-reductase inhibitors used for BPH in men with prostate enlargement. Finasteride primarily inhibits type 2 5-alpha-reductase, whereas dutasteride inhibits both type 1 and type 2.
Dutasteride therefore produces stronger suppression of circulating DHT, but the difference in DHT within prostate tissue is considerably smaller. Comparative clinical evidence does not show that greater serum DHT suppression automatically produces superior urinary symptom outcomes.
Both drugs work slowly, can reduce prostate volume, lower PSA and decrease the long-term risk of urinary retention and BPH-related surgery in appropriately selected men. Both can also affect sexual function.
The practical decision between finasteride and dutasteride should therefore be based on prostate size, progression risk, urinary findings, treatment duration, adverse effects, PSA monitoring and the overall treatment plan—not one laboratory or pharmacological difference alone.
For the broader BPH treatment pathway, see Benign Prostatic Hyperplasia and Enlarged Prostate .
The previous comparison explains Alpha Blockers vs 5-Alpha-Reductase Inhibitors for BPH .
If medication does not adequately control BPH or complications develop, the next guide covers BPH Surgery and Minimally Invasive Procedures .
Educational information only. Finasteride and dutasteride are prescription medications. Treatment choice, monitoring and changes to therapy should be discussed with a qualified healthcare professional.
